NBN GENE VARIABILITY IS ASSOCIATED WITH INCREASED RISK OF CNS RELAPSE AMONG CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Bartlomiej Tomasik, 133422

TARGETED LOCUS AMPLIFICATION & NEXT GENERATION SEQUENCING FOR THE DETECTION OF RECURRENT AND NOVEL GENE FUSIONS FOR IMPROVED TREATMENT DECISIONS IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Monique den Boer, 133423

TARGETING BET FAMILY PROTEINS IMPROVES THE THERAPEUTIC EFFICACY OF BCL-2 INHIBITION IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Sofie Peirs, 133424

PATIENT-REPORTED OUTCOMES FROM A GLOBAL PHASE 3 RANDOMIZED CONTROLLED TRIAL OF INOTUZUMAB OZOGAMICIN VERSUS STANDARD CARE FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, H Kantarjian, 133425

DELETIONS OF IKZF1 GENE, BUT NOT GENETIC RISK GROUPS, DEFINED BY COPY-NUMBER ALTERATIONS, ARE PROGNOSTICALLY SIGNIFICANT FOR PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA ON ALL-MB 2008 PROTOCOL

EHA Library, Grigory Tsaur, 133426

LACK OF PROGNOSTIC SIGNIFICANCE OF CD20 EXPRESSION IN ADULTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE, B-CELL PRECURSOR ALL TREATED ACCORDING TO MRD-ORIENTED PROTOCOLS

EHA Library, Josep-Maria Ribera, 133427

PROTEIN PHOSPHATASE 4 REGULATORY SUBUNIT 2 (PPP4R2) IS RECURRENTLY DELETED IN ACUTE MYELOID LEUKEMIA (AML) AND REQUIRED FOR EFFICIENT DNA DOUBLE STRAND BREAK REPAIR

EHA Library, Julia K. Herzig, 133428

PRELEUKEMIC CLONES IN NPM1-MUTATED AML MAY BE ASSOCIATED WITH EVOLUTION TO MYELODYSPLASTIC SYNDROME (MDS) OR MYELOPROLIFERATIVE NEOPLASM (MPN)

EHA Library, Sarah Morin, 133429

CLINICAL, HEMATOLOGICAL, BIOLOGIC AND MOLECULAR CHARACTERISTICS IN PATIENTS WHO DEVELOP ACUTE MYELOID LEUKEMIA FROM CHRONIC MYELOMONOCYTIC LEUKEMIA

EHA Library, Klaus Geissler, 133430

MOLECULAR CLASSIFICATION AND COMPARATIVE ANALYSIS OF ACUTE MYELOID LEUKEMIA MULTI-OMICS DATA USING THE INTERACTIVE HEMAP RESOURCE

EHA Library, Jake Lin, 133431

SOMATIC DDX41 P.R525H MUTATION CAUSES GROWTH DEFECT IN HEMATOPOIETIC CELLS

EHA Library, Hirotaka Matsui, 133432

WHOLE EXOME SEQUENCING REVEALS NOVEL CANDIDATE GENES IN FAMILIAL MDS/AML

EHA Library, Ana Rio-Machin, 133433

CLONAL EVOLUTION IN NPM1 MUTATED ACUTE MYELOID LEUKEMIA (AML)

EHA Library, Sibylle Cocciardi, 133434

POOR PROGNOSIS MONOSOMIC AND TRISOMIC ACUTE MYELOID LEUKEMIA ASSOCIATES WITH CHECKPOINTS AND CDC20 DEREGULATION: A NOVEL LEUKEMOGENIC MECHANISM AND THERAPEUTIC TARGETS

EHA Library, Giorgia Simonetti, 133435

IN ACUTE MYELOID LEUKEMIA WITH COMPLEX KARYOTYPE CHROMOTHRIPSIS IS LINKED TO TP53 ALTERATION AND CELL CYCLE IMPAIRMENT

EHA Library, Frank Rücker, 133436

PHYSIOPATHOLOGICAL MECHANISM OF LEUKEMIC PREDISPOSITION IN ANKRD26-RD PATIENTS

EHA Library, Alessandro Donada, 133437

NOTCH SIGNALLING INHIBITION AS A MULTI-TARGET THERAPY TO OVERCOME BONE MARROW MICROENVIRONMENT-MEDIATED DRUG RESISTANCE IN AML

EHA Library, Paul Takam Kamga, 133438

INTEGRATIVE ANALYSIS OF LINCRNA EXPRESSION IN 922 ACUTE MYELOID LEUKEMIA PATIENTS REVEALS MULTIPLE PROGNOSTIC GENE SIGNATURES

EHA Library, Dominik Beck, 133439

ENANTIOMER-SPECIFIC AND PARACRINE LEUKEMOGENICITY OF MUTANT IDH METABOLITE 2-HYDROXYGLUTARATE

EHA Library, Anuhar Chaturvedi, 133440

INVOLVEMENT OF THE TRANSCRIPTION FACTOR ASCL2 IN NORMAL AND LEUKEMIC HEMATOPOIESIS

EHA Library, Mallorie Dépond-Mangean, 133441

DIFFERENTIAL DNA METHYLATION IN CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA IS LINKED TO ALTERED GENE EXPRESSION OF ENHANCER TARGET GENES

EHA Library, Ying Qu, 133442

IN VIVO SHRNA SCREEN IDENTIFIES SPLICING FACTOR RBM25 AS A TUMOR SUPPRESSOR IN ACUTE MYELOID LEUKEMIA

EHA Library, Ying Ge, 133443

HIGH MTORC1 ACTIVITY DRIVES GLUCOSE METABOLISM ADDICTION AND SENSITIVITY TO G6PD INHIBITION IN ACUTE MYELOID LEUKEMIA CELLS

EHA Library, Laury Poulain, 133444

ALVOCIDIB POTENTIATES THE ACTIVITY OF ABT-199 IN NONCLINICAL MODELS OF ACUTE MYELOID LEUKEMIA

EHA Library, Clifford Whatcott, 133445

FIRST-IN-CLASS CDK7 INHIBITOR, INDUCES ROBUST APOPTOSIS IN ACUTE MYELOID LEUKEMIA AND DEMONSTRATES DURABLE IN VIVO EFFICACY

EHA Library, Yoon Jong Choi, 133446

IDENTIFICATION OF A NOVEL STAT5 INHIBITOR TO INTERFERE WITH THE ONCOGENIC ACTIVITIES OF STAT5 IN AML

EHA Library, Bettina Wingelhofer, 133447

IMPAIRED BASE EXCISION REPAIR GLYCOSYLASE/AP ENDONUCLEASE ACTIVITY CONTRIBUTES TO CYTARABINE RESISTANCE IN ACUTE MYELOID LEUKEMIA

EHA Library, Werner Olipitz, 133448

DOUBLE INACTIVATION OF TET2 AND TET3 INDUCES HYPOMETHYLATING AGENT-SENSITIVE ACUTE MYELOID LEUKEMIA

EHA Library, Koichiro Maie, 133449

NGS IDENTIFIES MUTATIONS PROGNOSTIC OF RELAPSE AFTER ALLO-SCT AND NOVEL CLONE EMERGENCE AT DISEASE RECURRENCE: IMPLICATIONS FOR STRATEGIES TO PREVENT POST ALLO-SCT RELAPSE.

EHA Library, Lynn Quek, 133450

HIGH PREDICTIVE VALUE OF COMBINED WT1 AND FLOW CYTOMETRY-BASED PRE TRANSPLANT MINIMAL RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA

EHA Library, Fabio Guolo, 133451

PROGNOSIS AND TARGETED TREATMENT OF AML WITH DIFFERENT IDH MUTATIONS COULD BE INFLUENCED BY ADDITIONAL MUTATIONS

EHA Library, Tamara Alpermann, 133452

DNMT3A AND IDH1 MUTATIONS WORSEN THE PROGNOSIS OF ELN GOOD RISK (CEBPA OR NPM1 MUTATED/FLT3 UNMUTATED) AML PATIENTS

EHA Library, Jana Marková, 133453

MUTATIONAL SPECTRUM ANALYSIS BY NEXT GENERATION SEQUENCING IN ADULT ACUTE MYELOID LEUKEMIA

EHA Library, Jianxiang Wang, 133454

NANOG EXPRESSION AS A RESPONSIVE BIOMARKER DURING TREATMENT WITH HEDGEHOG SIGNAL INHIBITOR IN ACUTE MYELOID LEUKEMIA

EHA Library, Seiji Kakiuchi, 133455

A NOVEL NEXT-GENERATION SEQUENCING BASED ASSAY FOR FLT3/ITD MUTATIONS IS SENSITIVE AND SPECIFIC AND CAN BE USED TO DETECT MINIMAL RESIDUAL DISEASE IN AML PATIENTS

EHA Library, Mark J Levis, 133456

AN EX VIVO NATIVE ENVIRONMENT PRECISION MEDICINE TEST SHOWS HIGH CLINICAL CORRELATION WITH RESPONSES TO FIRST LINE ACUTE MYELOID LEUKEMIA TREATMENT

EHA Library, Juan Ballesteros, 133457

RECURSIVE PARTITIONING ANALYSIS FOR GENETIC STRATIFICATION AND PROGNOSTICATION OF ACUTE MYELOID LEUKAEMIA

EHA Library, Shaun Fleming, 133458

CD7 AND CD34 CO-EXPRESSION IDENTIFY A SUBPOPULATION OF NUCLEOPHOSMIN 1-MUTATED ACUTE MYELOID LEUKEMIA (NPM1+ AML) PATIENTS WITH INCREASED RISK OF RELAPSE.

EHA Library, Anna Porwit, 133459

IMPACT OF FIRST LINE ARSENIC TRIOXIDE AND RETINOIC ACID TREATMENT ON OUTCOME IN THERAPY-RELATED ACUTE PROMYELOCYTIC LEUKEMIA PATIENTS

EHA Library, Sabine Kayser, 133460

AZACITIDINE (AZA) VS CONVENTIONAL CARE REGIMENS (CCR) IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WITH MYELODYSPLASIA-RELATED CHANGES (MRC) IN AZA-AML-001 PER CENTRAL REVIEW

EHA Library, John F Seymour, 133461

IMPACT OF PHYSICIANS’ CHARACTERISTICS ON DECISION MAKING IN ELDERLY ACUTE MYELOID LEUKEMIA

EHA Library, Pierre Bories, 133462

THE ADDITION OF GEMTUZUMAB OZAGAMICIN (GO) TO INTENSIVE CHEMOTHERAPY SIGNIFICANTLY IMPROVES COMPLETE RESPONSES CR RATES AND OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA

EHA Library, Chiara Sartor, 133463

HOSPITALIZATION FOR TREATMENT-EMERGENT ADVERSE EVENTS (TEAE) IN OLDER (≥65 YEARS) PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WITH >30% MARROW BLASTS IN THE PHASE 3 AZA-AML-001 STUDY

EHA Library, John F Seymour, 133464

PHARMACEUTICAL TARGETING OF PYRUVATE DEHYDROGENASE KINASES IN T(8;21) ACUTE MYELOID LEUKEMIA

EHA Library, Hüsün Kizilkaya, 133465

HOPX IS A HEMATOPOIETIC STEM CELL MARKER AND ITS HIGH EXPRESSION PREDICTS CHEMORESISTANCE IN DE NOVO ACUTE MYELOID LEUKEMIA PATIENTS

EHA Library, Chien-Chin Lin, 133466

KIT MUTATIONS INCREASE THE RELAPSE RISK IN PATIENTS WITH AML WITH T(8;21) OR RUNX1-RUNX1T1 BUT NOT IN PATIENTS WITH INV(16) OR CBFB/MYH11: A SUBGROUP ANALYSIS OF CETLAM PROTOCOLS 2003 & 2012

EHA Library, Marta PRATCORONA, 133467

LONGITUDINAL EVALUATION OF T-CELLS IN CLINICAL MONOCLONAL B-CELL LYMPHOCYTOSIS (MBL)

EHA Library, Sameer Parikh, 133468

COPY NUMBER ANALYSIS OF THE BIRC3 GENE BY DROPLET DIGITAL PCR IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH 11Q DELETION

EHA Library, Sara Raponi, 133469

CLONAL EVOLUTION IN CLL IS ASSOCIATED WITH AN UNMUTATED IGHV STATUS, MUTATED TP53 AND SHORTER SURVIVAL

EHA Library, Claudia Haferlach, 133470

EPIGENETIC REGULATION OF ROR1 IN CHRONIC LYMPHOCYTIC LEUKEMIA DEFINES PREFERABLE TARGET FOR COMBINED EPIGENETIC-AND IMMUNE-THERAPY

EHA Library, Katarzyna Skorka, 133472

COMPLEX KARYOTYPE AS IDENTIFIED BY CHROMOSOME BANDING ANALYSIS IS ASSOCIATED WITH SHORTER OVERALL SURVIVAL IN CLL INDEPENDENT OF TP53 ALTERATION AND IGHV MUTATION STATUS

EHA Library, Claudia Haferlach, 133473

IMPROVING THE DIFFERENTIAL DIAGNOSIS OF CD5+ B-LYMPHOPROLIFERATIVE DISORDERS

EHA Library, Andy Rawstron, 133474

REFINED KARYOTYPE-BASED PROGNOSTIC STRATIFICATION OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH A VERY LOW RISK GENETIC PROFILE

EHA Library, Ilaria Del Giudice, 133475

PRO-APOPTOTIC EFFECTS OF PRIMA-1MET CORRELATE WITH NOXA GENE INDUCTION IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS

EHA Library, Zuzana Jaskova, 133476

PILOT STUDY TO ASSESS REAGENT AND INSTRUMENT QUALITY FOR REPRODUCIBLE DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA: AN ESCCA AND ERIC HARMONISATION PROJECT

EHA Library, Andy Rawstron, 133477

THE SYK\JAK INHIBITOR CERDULATINIB SHOWS PROMISING IN VITRO ACTIVITY IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Andrew J. Steele, 133478

SAFETY, EFFICACY AND IMMUNE EFFECTS OF VENETOCLAX 400 MG DAILY IN PATIENTS (PTS) WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

EHA Library, Mary Ann Anderson, 133479

IBRUTINIB FOR RELAPSED CLL PATIENTS OLDER THAN 75 YEARS: PROVEN EFFICACY, TOXICITIES TO KNOW

EHA Library, Anne-Sophie Michallet, 133480

MUTATION ANALYSIS BY TARGETED NEXT GENERATION SEQUENCING IN ULTRA HIGH RISK CLL PATIENTS TREATED WITHIN THE CLL2O STUDY

EHA Library, Sven Estenfelder, 133481

IDELALISIB IN COMBINATION WITH RITUXIMAB IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) / SMALL LYMPHOCYTIC LYMPHOMA (SLL): REAL-WORLD EXPERIENCE THROUGH AN EARLY ACCESS PROGRAM IN EUROPE AND AUSTRALIA

EHA Library, Julio Delgado, 133482

CHROMOSOME 8 ABNORMALITIES ARE ASSOCIATED WITH AN EVEN WORSE OUTCOME AND KARYOTYPE COMPLEXITY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND TP53 ABERRATIONS

EHA Library, Anna Puiggros, 133483

OUTCOMES WITH SINGLE-AGENT IBRUTINIB BY PRIOR LINE OF THERAPY AND FOLLOWING IBRUTINIB DISCONTINUATION IN PATIENTS WITH CLL: ANALYSES FROM PHASE 3 STUDIES

EHA Library, Peter Hillmen, 133484

SINGLE-AGENT IBRUTINIB VS STANDARD OF CARE FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): AN ADJUSTED COMPARISON OF RESONATE™ WITH THE CLLEAR DATABASE

EHA Library, Michael Doubek, 133485

NO IMPROVEMENT IN LONG-TERM OVERALL SURVIVAL AFTER THE INTRODUCTION OF CHEMO(IMMUNO)THERAPY FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS BELONGING TO STEREOTYPED SUBSET #2

EHA Library, Panagiotis Baliakas, 133486

VENETOCLAX IS ACTIVE IN CLL PATIENTS WHO HAVE RELAPSED AFTER OR ARE REFRACTORY TO IBRUTINIB OR IDELALISIB

EHA Library, Steven E Coutre, 133487

SOMATIC MUTATIONS IN NEWLY-DIAGNOSED CHRONIC MYELOID LEUKEMIA DETECTED BY WHOLE-EXOME SEQUENCING

EHA Library, Chiaki Nakaseko, 133488

ROCK AS THERAPEUTICAL TARGET FOR MORGANA LOW CML

EHA Library, Stefania Rocca, 133489

A NOVEL C-TERMINAL HSP90 INHIBITOR WITH THERAPEUTIC EFFECT IN IMATINIB RESISTANT CML.

EHA Library, Sanil Bhatia, 133490

RESISTANCE IN CHRONIC MYELOID LEUKEMIA: THERAPEUTIC TARGETING OF ESCAPE VIA CSF2RB

EHA Library, Constance Becker, 133491

MITOCHONDRIAL DNA MUTATIONS IDENTIFY CLONAL HETEROGENEITY IN CHRONIC MYELOID LEUKAEMIA

EHA Library, Ilaria S. Pagani, 133492

CLONAL STRUCTURES OF LEUKAEMIA STEM CELL POPULATIONS IN MYELOID BLAST PHASE CHRONIC MYELOID LEUKAEMIA

EHA Library, Paresh Vyas, 133493

ROLE OF THE AURORA KINASE A AXIS IN IMATINIB RESISTANCE OF CHRONIC MYELOID LEUKEMIA CD34+ PROGENITORS

EHA Library, Manuela Mancini, 133494

PRESENCE OF SOMATIC AND GERMLINE MUTATIONS IN EPIGENETIC MODIFIERS IN CML-CP

EHA Library, Georgios Nteliopoulos, 133495

ASSESSMENT OF BCR-ABL1 TRANSCRIPT LEVELS BY DIGITAL PCR (DPCR) IN 116 PH+ CML PATIENTS TREATED WITH TIROSIN KINASE INHIBITORS (TKIS): A COMPARATIVE ANALYSIS BETWEEN DPCR AND QPCR.

EHA Library, Simona Bernardi, 133496

MOLECULAR RESPONSES OF B2A2 BCR-ABL1 TRANSCRIPT ARE INFERIOR TO B3A2 TYPE IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA AT CHRONIC PHASE TREATED WITH FRONTLINE IMATINIB -TAIWAN CML STUDY

EHA Library, Ming-Chung Wang, 133497

THE INCIDENCE AND NATURAL HISTORY OF DASATINIB COMPLICATIONS IN THE TREATMENT OF CHRONIC MYELOID LEUKAEMIA

EHA Library, Lucy Fox, 133498

THE HOCT1/ABCB1 DIPLOTYPE IS ASSOCIATED WITH COMPLETE CYTOGENETIC RESPONSE AND TOLERABILITY TO IMATINIB IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA

EHA Library, Sara Galimberti, 133499

REAL-LIFE COMPARISON OF DASATINIB AND NILOTINIB AS SECOND-LINE THERAPY AFTER IMATINIB FAILURE FOR CHRONIC PHASE CML

EHA Library, Mario Tiribelli, 133500

FACTORS THAT INFLUENCE PATIENT WILLINGNESS TO ATTEMPT TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKAEMIA

EHA Library, David Ross, 133501

GENETIC VARIABILITY OF OXIDATIVE STRESS AND DNA REPAIR GENES – POTENTIAL PROGNOSTIC AND THERAPEUTIC BIOMARKERS IN CHRONIC MYELOID LEUKEMIA

EHA Library, Ana Cristina Gonçalves, 133502

LANDMARK ANALYSES IN THE PIVOTAL PONATINIB PACE TRIAL: IMPACT OF EARLY RESPONSES ON 3-YEAR OUTCOMES IN HEAVILY PRETREATED CP-CML PATIENTS

EHA Library, Michele Baccarani, 133503

BCR-ABL1 TRANSCRIPT LEVEL ON DAY+28 CAN PREDICT EARLY MOLECULAR RESPONSE AT 3 MONTHS AND MAJOR MOLECULAR RESPONSE AT 12 MONTHS IN CHRONIC MYELOID LEUKEMIA PATIENTS WHO TREATED WITH FRONTLINE DASATINIB

EHA Library, Won Sik Lee, 133504

THE IMPACT OF EARLY MOLECULAR RESPONSE ON LONG-TERM OUTCOMES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) TREATED WITH DASATINIB OR IMATINIB FROM THE DASISION TRIAL

EHA Library, Frank Stegelmann, 133505

IMPACT OF AZACITIDINE THERAPY ON OVERALL SURVIVAL OF NEWLY DIAGNOSED PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES: A POST HOC ANALYSIS OF THE ERASME STUDY

EHA Library, Regina García, 133506

IMPACT OF BONE MARROW FIBROSIS IN RESPONSE TO AZACITIDINE IN 94 PATIENTS WITH MYELODISPLASTIC SYNDROMES (MDS), CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) AND ACUTE MYELOID LEUKEMIA

EHA Library, Gianluigi Reda, 133507

AGE DISTRIBUTION OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) IN GERMANY AND THEIR PROGNOSIS ACCORDING TO THE INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS): DATA FROM THE REGULAR CARE MDS REGISTRY

EHA Library, H Tilman Steinmetz, 133508

VALIDATION OF PROGNOSTIC SCORING SYSTEMS FOR MYELODYSPLASTIC SYNDROMES IN THE SWEDISH MDS-REGISTER

EHA Library, Daniel Moreno Berggren, 133509

EXPRESSION OF TUBB GENE IN MYELODYSPLASTIC SYNDROME WITH OR WITHOUT EVOLUTION TO LEUKEMIA

EHA Library, Yan Ma, 133510

HIDDEN MDS: A PROSPECTIVE STUDY TO CONFIRM OR EXCLUDE MDS IN PATIENTS WITH ANEMIA OF UNCERTAIN ETIOLOGY.

EHA Library, Jose Maria Bastida Bermejo, 133511

MANAGEMENT OF IRON OVERLOAD WITH DEFERASIROX IN VARIOUS HEMATOLOGICAL MALIGNANCIES – REAL WORLD EXPERIENCES FROM THE GERMAN NON-INTERVENTIONAL STUDY EXSEPT

EHA Library, Forian Nolte, 133512

CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES (MDS) IN DAILY PRACTICE: A POPULATION-BASED STUDY AMONG 8912 PATIENTS DIAGNOSED IN THE NETHERLANDS FROM 2001 TO 2014

EHA Library, Avinash Dinmohamed, 133513

LEVELS OF TRANSFUSION BURDEN AND ASSOCIATED COSTS FOR PATIENTS WITH TRANSFUSION-DEPENDENT MYELODYSPLASTIC SYNDROMES

EHA Library, Amy Dezern, 133514

THE INCORPORATION OF COMORBIDITIES IN THE PROGNOSTICATION OF PATIENTS WITH LOWER-RISK MDS.

EHA Library, Teresa Knight Asorey, 133515

STROMAL MICROENVIRONMENT COMPONENTS DAMAGE IN PATIENTS WITH GRAFT FAILURE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION

EHA Library, Nataliya Petinati, 133516

SPONTANEOUS REMISSION IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA - RETURN TO HEALTH OR TRANSITION INTO MALIGNANCY?

EHA Library, Eva-Stina Kairemo, 133517

UNAFFECTED MYELOID DIFFERENTIATION OF IPS CELLS DERIVED FORM A CYCLIC NEUTROPENIA (CYN) PATIENT WITH ELANE MUTATION

EHA Library, Azadeh Zahabi, 133518

OUTCOME OF ADOLESCENT AND YOUNG ADULTS WITH ACQUIRED APLASTIC ANEMIA TREATED WITH IMMUNOSUPPRESSIVE THERAPY IN COMPARISON WITH CHILDREN AND OLDER ADULTS

EHA Library, Aurélie Cabannes-Hamy, 133519

A PHASE 1 SINGLE-ASCENDING-DOSE CLINICAL STUDY OF RA101495, A SUBCUTANEOUSLY ADMINISTERED SYNTHETIC MACROCYCLIC PEPTIDE INHIBITOR OF COMPLEMENT C5 FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

EHA Library, Jeffrey Johnston, 133520

THE PRESENCE OF A PNH CLONE INFLUENCES THE KINETICS OF RESPONSE TO IMMUNOSUPPRESSIVE THERAPY (IST) IN APLASTIC ANEMIA (AA) PATIENTS.

EHA Library, Emilie Nevill, 133521

A CLINICAL SIGNIFICANCE AND TIME-DEPENDENT CHANGE OF PNH CLONE SIZE IN PATIENTS WITH BONE BARROW FAILURE SYNDROME: JAPANESE MULTI-CENTRE PROSPECTIVE STUDY

EHA Library, Yukari Shirasugi, 133522